Why Zepto Life Technology’s FDA breakthrough status matters for infectious disease diagnostics
Zepto’s FungiFlex brings liquid biopsy to invasive mold infections. The FDA designation tests whether faster fungal diagnosis can change care.
Medical Devices & Diagnostics
Pharma & Biotech
Can Sanofi’s venglustat priority review change the treatment outlook for type 3 Gaucher disease?
Sanofi’s venglustat could target neurological type 3 Gaucher disease. The FDA review now tests whether rare disease care can shift.
Medical Devices & Diagnostics
How Philips’ Elevate Plus could change abdominal, breast and thyroid ultrasound workflows
Philips’ Elevate Plus puts AI inside ultrasound workflows. The real test is whether hospitals see faster scans and fewer repeat exams.
Pharma & Biotech
Roche’s giredestrant FDA review raises the stakes in adjuvant breast cancer treatment
Find out how Roche’s giredestrant FDA priority review could reshape endocrine therapy in early breast cancer.
Pharma & Biotech
Can salanersen help Biogen defend its rare neurology franchise beyond Spinraza?
Find out how Biogen’s salanersen could reshape spinal muscular atrophy treatment after FDA breakthrough therapy status.
Medical Devices & Diagnostics
Insulet’s next diabetes technology challenge is not control alone, it is usability at scale
Find out how Insulet’s Omnipod 6 and fully closed-loop data could reshape automated insulin delivery for diabetes care.
Pharma & Biotech
Pfizer’s Phase 2b obesity data put monthly GLP-1 dosing back in investor focus
Find out how Pfizer’s berobenatide Phase 2b data could reshape monthly GLP-1 obesity treatment and late-stage trial strategy.
Medical Devices & Diagnostics
Can Dexcom G7 reshape CGM adoption for type 2 diabetes patients not using insulin?
Find out how Dexcom G7 data could reshape CGM adoption for type 2 diabetes patients not using insulin.
Pharma & Biotech
Corcept’s Korlym data put hypercortisolism back in focus for cardiometabolic disease
Read how Corcept’s ADA data could reshape hypercortisolism screening in difficult-to-control type 2 diabetes and GLP-1 care.
Pharma & Biotech
Why MAIA Biotechnology’s ateganosine program is entering a decisive lung cancer development phase
Find out how MAIA Biotechnology’s ateganosine trials could shape the next phase of lung cancer drug development today.